MalnutritionBEEDNCT02812615
The Bangladesh Environmental Enteric Dysfunction Study
A study testing Egg, Milk and Albendazole/Pyrantel Pamoate in people with Malnutrition and Infection, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
Trial summary
This is a community-based intervention study which will be undertaken at Mirpur, Dhaka, Bangladesh. Participants will be recruited from two age groups: a child cohort (age 12 to 18 months) and an adult cohort (age 18 to 45 years). Read more about this study
- Who is it for?
- Ages 12 months to 45 years
- Conditions the study is for
- Malnutrition, Infection
- What is being tested?
- Egg, Milk and Albendazole/Pyrantel Pamoate
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,575 participants
- Where
- 1 siteBangladesh
- Study dates
- 16 Jul 2016to 30 Jun 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 months to 45 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Inclusion criteria for stunted children: All of the following criteria must be met for a subject to be eligible to participate in the study-
- Parent(s) willing to sign consent form
- Child age 12-18 months
- LAZ < -2
- Parent(s) willing to bring child to the study site every day for 3 months for nutritional therapy
- Parents willing to have child undergo laboratory investigations and upper GI endoscopy and biopsy if the child fails to respond to nutritional therapy
Show all 20Show fewer
- Inclusion criteria for children who are at risk of stunting: All of the following criteria must be met for a subject to be eligible to participate in the study -
- Parent(s) willing to sign consent form
- Child age 12-18 months
- LAZ between <-1 to -2
- Parent(s) willing to bring child to the study site every day for 2 months for nutritional therapy
- Parents willing to have child undergo endoscopy and biopsy if the child fails to respond to nutritional therapy
- Inclusion criteria for malnourished adults: All of the following criteria must be met for a subject to be eligible to participate in the study -
- Willing to sign consent form
- Age 18-45 years
- BMI < 18.5
- Willing to visit the study site every day for 2 months for nutritional therapy
- Willing to undergo endoscopy and biopsy if he/she fails to respond to nutritional therapy
- Selection criteria for adult controls:
- An equal number of age and sex matched adult controls will be enrolled form the subjects with functional dyspepsia (FD) with apparently normal health (normal BMI) and absence of organic diseases. FD subjects will be identified from the Gastroenterology outpatient department of Dhaka Medical College Hospital and international centre for diarrhoeal disease research, Bangladesh staff clinic who will undergo upper GI endoscopy for evaluation of dyspepsia and have normal endoscopic findings. Dyspepsia will be defined by pre-defined criteria (Rome III criteria) by a structured questionnaire which has been translated and validated in Bengali.
Who cannot join
- Exclusion criteria for stunted children: Meeting any of the following criteria will exclude a subject from study participation -
- Severe acute malnutrition (SAM), severe anemia (<8 g/dl), tuberculosis, other chronic diseases or any congenital disorder or deformity
- Diarrhoea: Ongoing episode of diarrhoea, history of persistent diarrhoea in the past month or history of acute diarrhoea in the past 7 days
- Known allergy to eggs or milk or milk intolerance
- Exclusion criteria for children who are at risk of stunting: Meeting any of the following criteria will exclude a subject from study participation -
- Severe acute malnutrition (SAM), severe anemia (<8 g/dl), tuberculosis, other chronic diseases or any congenital disorder or deformity
Show all 12Show fewer
- Diarrhoea: Ongoing episode of diarrhoea, history of persistent diarrhoea in the past month or history of acute diarrhoea in the past 7 days
- Known allergy to eggs or milk or milk intolerance
- Exclusion criteria for malnourished adults: Meeting any of the following criterions will exclude a subject from study participation-
- Severe anemia (<8 g/dl), tuberculosis and other chronic diseases including diabetes mellitus or any congenital disorder or deformity
- Pregnant women, lactating women, drug abusers, known psychiatric disorders
- High clinical suspicion of cancer or other chronic or acute diseases that may cause malnutrition. Adult participants who fulfilled the inclusion criteria and not excluded through history and clinical examination based exclusion criteria will undergo screening tests for confirmation.
Trial locations and contacts
1 site in 1 country.
Tahmeed Ahmed, PhD contact
Mustafa Mahfuz, MPH contact
Bangladesh1 site, 1 recruiting
- Recruiting
Mirpur
Dhaka, 1216
Tahmeed Ahmed, Ph.D, +88029827001-10 ext. 2300, tahmeed@icddrb.org
Mustafa Mustafa, MPH, 9840523-32 ext. 2304, mustafa@icddrb.org
About this study
Official title: Stunting and Bangladesh Environmental Enteric Dysfunction Study
This is a community-based intervention study which will be undertaken at Mirpur, Dhaka, Bangladesh. Participants will be recruited from two age groups: a child cohort (age 12 to 18 months) and an adult cohort (age 18 to 45 years). The child cohort will consist of stunted children (length for age Z score, LAZ < -2), children who are at risk of stunting (length for age Z score <-1 to -2) and child controls. The adult cohort will consist of malnourished adult cases (Body Mass Index <18.5) and adult controls. After screening the participants for any organic diseases and application of inclusion/exclusion criteria, they will receive nutrition interventions. Participants eligible for study will be tested for potential bio markers of environmental enteropathy (stool, urine and serum) once before and once after the nutritional intervention. Participants who will fail to respond to nutritional therapy (measured by anthropometric assessment) will become candidates for upper gastrointestinal endoscopy with biopsy. The study will include duodenal biopsies from a control group of children from University of Virginia Hospital in Charlottesville, Virginia who will undergo upper GI endoscopy as part of their clinical care as per the standard clinical protocol followed at the hospital. Adult controls (BMI > 18.5) for endoscopy will be collected from international centre for diarrhoeal disease research,Bangladesh staff clinic, Dhaka Medical College and Hospital (DMCH), Dhaka and Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.
Read the detailed description
Study design This will be a community-based intervention study. Survey, screening, enrollment of subjects will be done in Mirpur in Dhaka city.
Subjects Participants will be recruited from two age groups: a child cohort (age 12 to 18 months) and an adult cohort (age 18 to 45 years). The child cohort will consist of two groups of children- stunted children (LAZ score < -2) and children who are at risk of stunting (LAZ <-1 to -2). A group of malnourished adults (BMI <18.5) will also be enrolled from the parents of children and by a cross sectional survey from Mirpur area of Dhaka city.
Sample size:
Participants will be collected and recruited in a cross sectional manner. Based on a sample size calculation with 10% precision and 95% confidence interval, a minimum of 35 stunted children, 35 at risk of stunting children and 35 adults will be recruited. So, the final sample size for endoscopy is 105 subjects (35+35+35). As endoscopy is an invasive procedure, it was assumed that only one-third of those who would fail to respond after nutrition intervention would give consent for endoscopy. So, basic sample size was increased three times for a minimum of 105 (35 x 3) stunted children (LAZ <-2), 105 (35 x 3) children at risk of stunting (LAZ <-1 to 2) and 105 (35 X 3) malnourished adults (BMI < 18.5) who would fail to thrive. To achieve that 525 stunted children, 525 children at risk of stunting and 525 malnourished adults for nutrition interventions will be recruited as it was assumed that ~20% of each group will fail to respond despite the nutritional intervention. For that order of recruitment surveying at least 3977 (1312+2665) children 12-18 months old and 2100 adults based on the current prevalence of malnutrition in the two age groups is required. For adult control group, same number (35) of adult controls will be recruited from Dhaka Medical College and international centre for diarrhoeal disease research,Bangladesh staff clinic by convenient sampling method
Description of field site:
The study will be conducted among residents of Mirpur, one of the 21 administrative units of the nation's capital, Dhaka.
Recruitment, Screening and Consenting If the participants are interested to volunteer in the study, the designated staff will proceed to screening and consenting. Screening will consist of a review of the inclusion and exclusion criteria listed above. If the subject is eligible to participate, the process will proceed to consenting consisting of a thorough review of the written consent form in a manner appropriate for the child's parents' / participants literacy level. Prior to signing the consent form, they will have an opportunity to ask any questions about the study. If the Field Research Assistant (FRA) determines that participants have demonstrated adequate comprehension of the study, the consent form will be signed by the FRA and the child's parent(s) /adult participants. If the parent(s) / adult participants are not sufficiently literate to read and/or sign the consent form, consenting and a thumb impression will be obtained in the presence of a witness who is not associated with the study. The child's parent(s) / adult participants will be provided with a copy of the signed consent form.
Detailed procedure of Directly Observed Nutritional Therapy:
After enrollment, participants will receive daily directly observed nutritional therapy. Nutritional therapy consists egg and milk and will be provided by the study free of cost. Duration of nutrition interventions will be 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively and nutritional therapy will be delivered between the morning and mid day meal, anytime between 10:00 am to 11:30 am. Participants will be asked to come to the designated nutrition center (to be established at Mirpur) daily for nutritional therapy to avoid the issue of food sharing. A staff will visit the family's household if a participant defaults in coming to the nutrition center. In addition to the food based nutritional therapy, participants will receive the following nutritional and health support:
- Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) as per national guidelines
- Parents/caregivers will be given nutritional counselling
- For the child cohort, parents will be given one sachet of multiple micro-nutrient sprinkles per day for two months.
- Any inter-current illnesses detected by the study team will also be taken care of.
Food based nutritional therapy: Supplementation of the usual home diet with one egg, and 150 ml of whole milk which will provide an additional 178 kilo-calories, 11.1 g protein, and 11.5 g of fat to the daily diet of enrolled subjects. Sachets of multiple micro-nutrient powder will be provided for use at home at dinner.
In order to clarify the role of food-based nutritional therapy, there will be comparison subgroups of 40 stunted children and 40 children at risk of stunting who will be followed for 3 and 2 months respectively, without any nutritional therapy. At the end of the observation period of 3 and 2 months, nutritional therapy will be provided to these children same as that provided to the enrolled participants.
Discontinuation from the study: A child will be discontinued from the study and referred for medical evaluation if he/she shows reluctant to feed for consecutive 7 days which includes daily intake of 50% or less amount of food that will be offered. A new eligible child will be recruited in his position for nutritional intervention.
Collection of biological samples:
All biological samples (blood, urine, stool, duodenal aspirates, and endoscopic biopsies) will be collected as per the standard operative procedures (SOPs) which will be prepared for this protocol. A total amount of 5ml blood will be collected from each participant before and after nutritional intervention. Urine will be collected for Lactulose-Rhamnose assay, and for metabolomic studies; breath samples will be collected for testing for small intestinal bacterial overgrowth (SIBO). Second SIBO will be done 1-2 weeks prior to endoscopy so that the findings from the endoscopy can be compared to the breath tests. Fecal samples will be collected for biomarkers, Taqman array card (TAC) assays and Microbiome/Microbiota for age Z-score (MAZ)/Bug fluorescence-activated cell sorting.
Detailed procedure of Bio-marker testing
The bio-markers going to be tested for are-
Stool bio-markers
- Regeneration gene 1Beta
- Neopterin
- Myeloperoxidase
- Alpha-1-antitrypsin
- Calprotectin
- The TaqMan Array Card for enteropathogen
- Gut Microbiome analysis
- Bug Fluorescence-Activated Cell Sorting.
Urine bio-markers
- Lactulose-Rhamnose test
Blood bio-markers
- C- Reactive Protein
- Alpha-1-acid glycoprotein
- Soluble cluster of differentiation 14
- Kynurenine-Tryptophan Ratio
- Glucagon-like peptide-2
- Insulin-like growth factor-2
- Tissue Transglutaminase
- Ferritin
- Zinc
- Pepsinogen I/II Ratio
- Low density lipoprotein related receptor 1 (LRP1)
- Blood plasma metabolomics
Other proposed biomarkers
- Small intestinal bacterial overgrowth
After completion of nutritional therapy, all enrolled participants will have an assessment for response which will include:
- Anthropometric measurements
- Collection of one 5 ml blood sample for serum bio-markers of gut function and screening tests for the endoscopy with biopsy procedure, if the procedure is indicated for failure to thrive
- Collection of stool specimen for bio-markers of gut function
- Administration of lactulose-rhamnose solution and collection of urine for up to 2 hours for urine bio markers of gut function
At this time, the final inclusion criterion for endoscopy with biopsy will be evaluated to determine whether the participants failed nutritional therapy or had an adequate response, or have an underlying disease that caused the malnutrition. Failure of nutritional therapy in this study, or failure to respond, is defined in the absence of any other underlying diseases such as tuberculosis:
- LAZ score remains < -2 for stunted children cohort
- LAZ score remains < -1 for "at risk of stunting" children cohort
- BMI < 18.5 and < 10% increase in BMI for adults.
Participants who meet the study definition of "failure to respond" will be checked for presence of any secondary cause of malnutrition like tuberculosis, carcinoma, any parasitic infection etc. Stool microscopy for parasite identification will be done at icddr,b parasitology lab as soon as possible after collection of stool samples. If nothing conclusive can be found, the participants may be requested to undergo preparations for upper GI endoscopy with biopsy, as they may benefit from further evaluation to identify the potential cause(s) of intervention failure and to determine an appropriate therapeutic course. It will also benefit others by validating the non-invasive bio-marker signature of Environmental Enteric Dysfunction. Participants who will undergo endoscopy will receive necessary treatments according to diagnosis.
Participants having celiac disease and clotting disorder (tested by prothrombin time / International Normalized Ratio coagulopathy) will be excluded from the study. Endoscopy of upper gastrointestinal tract will be done as per standards recommended by North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN0, American College of Gastroenterology (ACG) and American Society for Gastrointestinal Endoscopy (ASGE).
- Conditions
- Malnutrition, Infection
- Being tested
- Egg, Milk, Albendazole/Pyrantel Pamoate, Nutritional counselling, Micronutrient sprinkles
- Keywords
- Environmental Enteric Dysfunction
- Medical subject headings
- Malnutrition, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EggDietary supplement
After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
MilkDietary supplement
After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
Albendazole/Pyrantel PamoateDrug
As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
Nutritional counsellingBehavioural
Parents/caregivers will be given nutritional counselling
Micronutrient sprinklesDietary supplement
For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
| Study group | Role | What they receive |
|---|---|---|
| Malnourished participants | Experimental | After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months. Receives: Dietary Supplement: Egg; Dietary Supplement: Milk; Drug: Albendazole/Pyrantel Pamoate; Behavioral: Nutritional counselling; Dietary Supplement: Micronutrient sprinkles |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Length for Age Z score
For stunted child participants, length and age data will be collected before and after the intervention period (3 months) and changes in length for age Z score will be measured.For at risk of stunting child participants, length and age data will be collected before and after the intervention period (2 months) and changes in length for age Z score will be measured.
Measured: baseline and 3 months
Change in Body Mass Index
For malnourished adult participants, height and and weight data will be collected before and after the intervention period (2 months) and changes in Body Mass Index will be measured.
Measured: baseline and 2 months
Secondary outcomes (19)
Change in stool Regeneration gene 1 Beta (Reg 1B) biomarker level
Reg1 is known to promote intestinal epithelial cell proliferation, regeneration and repair, and is up-regulated in a variety of enteric infections and inflammatory conditions. A commercial ELISA assay will be run on fecal samples to measure Reg 1 levels.
Measured: baseline and 3 months
Change in stool neopterin level
Neopterin is a product of the breakdown of cyclic guanosine monophosphate (cGMP) when released from phagocytic cells, and an increase in neopterin can be found with the activation of cellular immune response. So, increased neopterin in stools will be used as a marker for an inflammatory immune response in the intestinal epithelium.
Measured: baseline and 3 months
Change in stool myeloperoxidase level
Derived from azurophil granules, which are a specific marker of polymorphonuclear leukocytes (PMN) activity, myeloperoxidase (MPO) catalyzes the oxidation of substances through hydrogen peroxide (H2O2). The MPO H2O2-system has a toxic effect on many micro-organisms such as bacteria, fungi, viruses and mycoplasma. MPO determination in the stool reflects the inflammatory activity of Crohn's disease or ulcerative colitis. During inflammation in the intestinal mucosa, neutrophils migrate towards the gut mucosa and release myeloperoxidase from granulocytes which can be detected in stools and used as a marker of intestinal inflammation. A commercial ELISA kit will be used to measure myeloperoxidase in stool specimens.
Measured: baseline and 3 months
Change in stool Alpha-1-antitrypsin level
Alpha-1-antitrypsin is an acute phase protein predominantly made in the liver, but also in intestinal macrophages, monocytes, and epithelial cells and released during inflammation. The presence of alpha-1-antitrypsin in the stool is a marker of intestinal inflammation, intestinal permeability and protein loss. A commercial ELISA kit will be utilized to measure alpha-1-antitrypsin in stool specimens.
Measured: baseline and 3 months
Change in stool Calprotectin level
Calprotectin is released by activated neutrophils, and it accounts for more than 40% of the cytosolic proteins of neutrophils. Elevated concentrations of calprotectin can be measured in plasma, cerebrospinal fluid, synovial fluid, urine, and feces when inflammation is present or in malignant conditions. The high fecal calprotectin concentrations can be explained by increased turnover of leukocytes in the gut wall and increased migration of neutrophils into the gut lumen . The fecal calprotectin results are expressed in mg of calprotectin per kilogram of wet feces within a normal reference range of <50 mg/kg.
Measured: baseline and 3 months
Change in stool TaqMan Array Card (TAC) result
The TaqMan Array Card (TAC) system is a real-time polymerase chain reaction format that is used to detect multiple infection targets. An enteric TaqMan Array Card can detect 27 enteropathogens, including viruses and helminths Fecal samples will be spiked with extrinsic controls, and total nucleic acid will be extracted. TAC allows fast, accurate, and quantitative detection of a broad spectrum of enteropathogens.
Measured: baseline and 3 months
Change in gut microbiota maturity status
The human gut microbiota undergoes a defined postnatal developmental program of assembly over the first 2-3 years of life that is perturbed in children with undernutrition and is not durably repaired by existing therapeutic foods. While these studies have identified a link between microbiota maturity and anthropometric measures of healthy growth in early childhood, the relationship between histopathologically defined Environmental Enteric Dysfunction and the configuration/maturation of the microbiota in the small and large intestines has not been studied.
Measured: baseline and 3 months
Change in lactulose and rhamnose permeability test
The lactulose and rhamnose permeability test will be used to measure intestinal permeability. The synthetic disaccharide, lactulose, is minimally absorbed via the paracellular route and then excreted unchanged in the urine, while the monosaccharide sugar rhamnose, being smaller is usually completely absorbed in the small intestine and excreted unchanged in the urine. An elevated lactulose: rhamnose ratio indicates increased permeability.
Measured: baseline and 3 months
Change in blood C-reactive protein level
C-reactive protein (CRP) is an acute phase protein and can be detected during infection. It is a measurement of enteric permeability across the gut membrane. A commercial ELISA kit will be used to measure the levels of CRP in plasma samples.
Measured: baseline and 3 months
Change in blood Alpha-1-acid glycoprotein level
Alpha-1-acid glycoprotein is an acute phase protein. Increased levels are found in the serum during systemic tissue injury, inflammation and infection. A commercial ELISA kit will be utilized to measure the levels of alpha-1-acid glycoprotein in plasma specimens.
Measured: baseline and 3 months
Change in blood sCD14 level
sCD14 is a protein receptor for lipopolysaccharide (LPS). Similar to the principle behind the anti-LPS antibody assay, once the LPS or endotoxin containing particles enters the bloodstream from the intestinal mucosa, they are bound to sCD14. An increase in sCD14 indicates an increase in endotoxin or LPS entering the bloodstream from the intestinal mucosa .
Measured: baseline and 3 months
Change in blood kynurenine Tryptophan ratio
Tryptophan is an essential amino acid that is central to cellular respiration and neurotransmission, and is a key immune mediator. During inflammation, tryptophan is metabolized by indoleamine 2,3-dioxygenase (IDO) to the toxic metabolite kynurenine. IDO activity is measured by the ratio of kynurenine to tryptophan. IDO activity correlates with disease severity in patients with chronic inflammatory diseases .
Measured: baseline and 3 months
Change in blood Glucagon-like peptide-2 level
Glucagon-like peptide-2 (GLP-2) is a newly discovered gastrointestinal peptide with 33% sequence homology to glucagon. GLP-2 has attracted interest because of its potent endocrine/paracrine actions. The peptide results from expression of the glucagon gene in the intestinal mucosa, from where it is released mainly in response to luminal contact with unabsorbed nutrients. In addition to mucosal growth, GLP-2 enhances activities of several intestinal brush-border enzymes, and it delays gastric transit, thereby increasing the intestinal capacity for nutrient absorption. Thus, it appears that GLP-2 serves to ensure an optimal intestinal capacity.
Measured: baseline and 3 months
Change in blood ferritin level
Serum ferritin is widely recognized as an acute phase reactant and marker of acute and chronic inflammation, and is nonspecifically elevated in a wide range of inflammatory conditions.
Measured: baseline and 3 months
Change in blood zinc level
Scientists have explored the overlapping nature of zinc deficiency and environmental enteropathy, and presented evidence for their interaction. Environmental Enteropathy (EE) leads to impaired zinc homeostasis, predominantly due to reduced absorptive capacity arising from disturbed intestinal architecture, and zinc deficiency exacerbates several of the proposed pathways that underlie EE, including intestinal permeability, enteric infection, and chronic inflammation.
Measured: baseline and 3 months
Change in blood pepsinogen I & II level
Gastric acid has an important pathophysiological role in human beings. Appropriate levels of gastric acid are needed to adequately absorb many nutrients including minerals and vitamins. It is also a crucial part of the immune system. The hypochlorhydria induced by H. pylori infection may also result in alterations in the gut microbiota and contribute to small intestinal permeability changes and malabsorption,In this study, we also want to investigate serum pepsinogen I \& II to see their association with Environmental Enteric Dysfunction.
Measured: baseline and 3 months
Change in blood Low density lipoprotein related receptor 1 (LRP1) level
LRP1 is an endocytic receptor involved in trafficking at least 100 different molecules, including lipids and proteins/peptides involved in immune system function (e.g. antigen presentation) as well as viral proteins and toxins. The epigenetic data strongly suggest that LRP1 expression is reduced in stunted children compared to controls.
Measured: baseline and 3 months
Change in blood metabolomic profile
Gut inflammation is reflected in an altered serum metabolite profile; characterization of the metabolome can identify pathways and metabolite bio-markers that may be useful as a diagnostic for inflammation
Measured: baseline and 3 months
Change in small intestinal bacterial overgrowth (SIBO) status
Small intestine bacterial overgrowth (SIBO) is measured noninvasively by a hydrogen breath test, where oral glucose is administered and an increase of hydrogen in the breath SIBO of at least 12 parts per million is detected. Traditionally, SIBO has been considered a secondary condition that develops in the setting of altered intestinal anatomy, slowed intestinal motility, or aberrant gastrointestinal function.
Measured: baseline and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2016 (estimated)
- Study start16 Jul 2016
- Primary completion30 Jun 2022 (estimated)
- Study completion30 Jun 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for MalnutritionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,575 participants (estimated)
Sponsor and investigators
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
- Sponsor type
- University, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation, University of Virginia, University of Washington, Dhaka Medical College, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02812615
- Sponsor's protocol ID
- PR-16007
- Acronym
- BEED
- Status last verified
- Dec 2021
- First submitted
- 31 May 2016
- Last updated
- 11 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Pierce R, Jan NJ, Kumar P, Middleton J, Petri WA, Marie C. Persistent dysbiosis of duodenal microbiota in patients with controlled pediatric Crohn's disease after resolution of inflammation. Sci Rep. 2024 Jun 3;14(1):12668. doi: 10.1038/s41598-024-63299-y.
PubMed 38830904Hossain MS, Begum SMKN, Rahman MM, Parvez M, Mazumder RN, Sarker SA, Hasan MM, Fahim SM, Gazi MA, Das S, Mahfuz M, Ahmed T. Environmental enteric dysfunction and small intestinal histomorphology of stunted children in Bangladesh. PLoS Negl Trop Dis. 2023 Jan 19;17(1):e0010472. doi: 10.1371/journal.pntd.0010472. eCollection 2023 Jan.
PubMed 36656867Chen RY, Kung VL, Das S, Hossain MS, Hibberd MC, Guruge J, Mahfuz M, Begum SMKN, Rahman MM, Fahim SM, Gazi MA, Haque R, Sarker SA, Mazumder RN, Di Luccia B, Ahsan K, Kennedy E, Santiago-Borges J, Rodionov DA, Leyn SA, Osterman AL, Barratt MJ, Ahmed T, Gordon JI. Duodenal Microbiota in Stunted Undernourished Children with Enteropathy. N Engl J Med. 2020 Jul 23;383(4):321-333. doi: 10.1056/NEJMoa1916004.
PubMed 32706533Mahfuz M, Alam MA, Das S, Fahim SM, Hossain MS, Petri WA Jr, Ashorn P, Ashorn U, Ahmed T. Daily Supplementation With Egg, Cow Milk, and Multiple Micronutrients Increases Linear Growth of Young Children with Short Stature. J Nutr. 2020 Feb 1;150(2):394-403. doi: 10.1093/jn/nxz253.
PubMed 31665385Hossain MS, Das S, Gazi MA, Alam MA, Haque NMS, Mahfuz M, Ahmed T, Damman CJ. Association of faecal pH with childhood stunting: Results from a cross-sectional study. BMJ Paediatr Open. 2019 Sep 13;3(1):e000549. doi: 10.1136/bmjpo-2019-000549. eCollection 2019.
PubMed 31646200Mahfuz M, Das S, Mazumder RN, Masudur Rahman M, Haque R, Bhuiyan MMR, Akhter H, Sarker MSA, Mondal D, Muaz SSA, Karim ASMB, Borowitz SM, Moskaluk CA, Barratt MJ, Petri WA, Gordon JI, Ahmed T. Bangladesh Environmental Enteric Dysfunction (BEED) study: protocol for a community-based intervention study to validate non-invasive biomarkers of environmental enteric dysfunction. BMJ Open. 2017 Aug 11;7(8):e017768. doi: 10.1136/bmjopen-2017-017768.
PubMed 28801442
Study at a glance
From the registry record, last updated by the sponsor on 11 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Stunting and Bangladesh Environmental Enteric Dysfunction Study
- ClinicalTrials.gov ID
- NCT02812615
- Acronym / sponsor ID
- BEED / PR-16007
- Conditions
- Malnutrition, Infection
- Keywords
- Environmental Enteric Dysfunction
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 1,575 participants (estimated)
- Lead sponsor
- International Centre for Diarrhoeal Disease Research, BangladeshUniversity, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation, University of Virginia, University of Washington, Dhaka Medical College, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Study start
- 16 Jul 2016 (actual)
- Primary completion
- 30 Jun 2022 (estimated)
- Study completion
- 30 Jun 2022 (estimated)
- First posted
- 24 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a community-based intervention study which will be undertaken at Mirpur, Dhaka, Bangladesh. Participants will be recruited from two age groups: a child cohort (age 12 to 18 months) and an adult cohort (age 18 to 45 years). The child cohort will consist of stunted children (length for age Z score, LAZ < -2), children who are at risk of stunting (length for age Z score <-1 to -2) and child controls. The adult cohort will consist of malnourished adult cases (Body Mass Index <18.5) and adult controls. After screening the participants for any organic diseases and application of inclusion/exclusion criteria, they will receive nutrition interventions. Participants eligible for study will be tested for potential bio markers of environmental enteropathy (stool, urine and serum) once before and once after the nutritional intervention. Participants who will fail to respond to nutritional therapy (measured by anthropometric assessment) will become candidates for upper gastrointestinal endoscopy with biopsy. The study will include duodenal biopsies from a control group of children from University of Virginia Hospital in Charlottesville, Virginia who will undergo upper GI endoscopy as part of their clinical care as per the standard clinical protocol followed at the hospital. Adult controls (BMI > 18.5) for endoscopy will be collected from international centre for diarrhoeal disease research,Bangladesh staff clinic, Dhaka Medical College and Hospital (DMCH), Dhaka and Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.
Detailed description
Study design This will be a community-based intervention study. Survey, screening, enrollment of subjects will be done in Mirpur in Dhaka city.
Subjects Participants will be recruited from two age groups: a child cohort (age 12 to 18 months) and an adult cohort (age 18 to 45 years). The child cohort will consist of two groups of children- stunted children (LAZ score < -2) and children who are at risk of stunting (LAZ <-1 to -2). A group of malnourished adults (BMI <18.5) will also be enrolled from the parents of children and by a cross sectional survey from Mirpur area of Dhaka city.
Sample size:
Participants will be collected and recruited in a cross sectional manner. Based on a sample size calculation with 10% precision and 95% confidence interval, a minimum of 35 stunted children, 35 at risk of stunting children and 35 adults will be recruited. So, the final sample size for endoscopy is 105 subjects (35+35+35). As endoscopy is an invasive procedure, it was assumed that only one-third of those who would fail to respond after nutrition intervention would give consent for endoscopy. So, basic sample size was increased three times for a minimum of 105 (35 x 3) stunted children (LAZ <-2), 105 (35 x 3) children at risk of stunting (LAZ <-1 to 2) and 105 (35 X 3) malnourished adults (BMI < 18.5) who would fail to thrive. To achieve that 525 stunted children, 525 children at risk of stunting and 525 malnourished adults for nutrition interventions will be recruited as it was assumed that ~20% of each group will fail to respond despite the nutritional intervention. For that order of recruitment surveying at least 3977 (1312+2665) children 12-18 months old and 2100 adults based on the current prevalence of malnutrition in the two age groups is required. For adult control group, same number (35) of adult controls will be recruited from Dhaka Medical College and international centre for diarrhoeal disease research,Bangladesh staff clinic by convenient sampling method
Description of field site:
The study will be conducted among residents of Mirpur, one of the 21 administrative units of the nation's capital, Dhaka.
Recruitment, Screening and Consenting If the participants are interested to volunteer in the study, the designated staff will proceed to screening and consenting. Screening will consist of a review of the inclusion and exclusion criteria listed above. If the subject is eligible to participate, the process will proceed to consenting consisting of a thorough review of the written consent form in a manner appropriate for the child's parents' / participants literacy level. Prior to signing the consent form, they will have an opportunity to ask any questions about the study. If the Field Research Assistant (FRA) determines that participants have demonstrated adequate comprehension of the study, the consent form will be signed by the FRA and the child's parent(s) /adult participants. If the parent(s) / adult participants are not sufficiently literate to read and/or sign the consent form, consenting and a thumb impression will be obtained in the presence of a witness who is not associated with the study. The child's parent(s) / adult participants will be provided with a copy of the signed consent form.
Detailed procedure of Directly Observed Nutritional Therapy:
After enrollment, participants will receive daily directly observed nutritional therapy. Nutritional therapy consists egg and milk and will be provided by the study free of cost. Duration of nutrition interventions will be 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively and nutritional therapy will be delivered between the morning and mid day meal, anytime between 10:00 am to 11:30 am. Participants will be asked to come to the designated nutrition center (to be established at Mirpur) daily for nutritional therapy to avoid the issue of food sharing. A staff will visit the family's household if a participant defaults in coming to the nutrition center. In addition to the food based nutritional therapy, participants will receive the following nutritional and health support:
- Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) as per national guidelines
- Parents/caregivers will be given nutritional counselling
- For the child cohort, parents will be given one sachet of multiple micro-nutrient sprinkles per day for two months.
- Any inter-current illnesses detected by the study team will also be taken care of.
Food based nutritional therapy: Supplementation of the usual home diet with one egg, and 150 ml of whole milk which will provide an additional 178 kilo-calories, 11.1 g protein, and 11.5 g of fat to the daily diet of enrolled subjects. Sachets of multiple micro-nutrient powder will be provided for use at home at dinner.
In order to clarify the role of food-based nutritional therapy, there will be comparison subgroups of 40 stunted children and 40 children at risk of stunting who will be followed for 3 and 2 months respectively, without any nutritional therapy. At the end of the observation period of 3 and 2 months, nutritional therapy will be provided to these children same as that provided to the enrolled participants.
Discontinuation from the study: A child will be discontinued from the study and referred for medical evaluation if he/she shows reluctant to feed for consecutive 7 days which includes daily intake of 50% or less amount of food that will be offered. A new eligible child will be recruited in his position for nutritional intervention.
Collection of biological samples:
All biological samples (blood, urine, stool, duodenal aspirates, and endoscopic biopsies) will be collected as per the standard operative procedures (SOPs) which will be prepared for this protocol. A total amount of 5ml blood will be collected from each participant before and after nutritional intervention. Urine will be collected for Lactulose-Rhamnose assay, and for metabolomic studies; breath samples will be collected for testing for small intestinal bacterial overgrowth (SIBO). Second SIBO will be done 1-2 weeks prior to endoscopy so that the findings from the endoscopy can be compared to the breath tests. Fecal samples will be collected for biomarkers, Taqman array card (TAC) assays and Microbiome/Microbiota for age Z-score (MAZ)/Bug fluorescence-activated cell sorting.
Detailed procedure of Bio-marker testing
The bio-markers going to be tested for are-
Stool bio-markers
- Regeneration gene 1Beta
- Neopterin
- Myeloperoxidase
- Alpha-1-antitrypsin
- Calprotectin
- The TaqMan Array Card for enteropathogen
- Gut Microbiome analysis
- Bug Fluorescence-Activated Cell Sorting.
Urine bio-markers
- Lactulose-Rhamnose test
Blood bio-markers
- C- Reactive Protein
- Alpha-1-acid glycoprotein
- Soluble cluster of differentiation 14
- Kynurenine-Tryptophan Ratio
- Glucagon-like peptide-2
- Insulin-like growth factor-2
- Tissue Transglutaminase
- Ferritin
- Zinc
- Pepsinogen I/II Ratio
- Low density lipoprotein related receptor 1 (LRP1)
- Blood plasma metabolomics
Other proposed biomarkers
- Small intestinal bacterial overgrowth
After completion of nutritional therapy, all enrolled participants will have an assessment for response which will include:
- Anthropometric measurements
- Collection of one 5 ml blood sample for serum bio-markers of gut function and screening tests for the endoscopy with biopsy procedure, if the procedure is indicated for failure to thrive
- Collection of stool specimen for bio-markers of gut function
- Administration of lactulose-rhamnose solution and collection of urine for up to 2 hours for urine bio markers of gut function
At this time, the final inclusion criterion for endoscopy with biopsy will be evaluated to determine whether the participants failed nutritional therapy or had an adequate response, or have an underlying disease that caused the malnutrition. Failure of nutritional therapy in this study, or failure to respond, is defined in the absence of any other underlying diseases such as tuberculosis:
- LAZ score remains < -2 for stunted children cohort
- LAZ score remains < -1 for "at risk of stunting" children cohort
- BMI < 18.5 and < 10% increase in BMI for adults.
Participants who meet the study definition of "failure to respond" will be checked for presence of any secondary cause of malnutrition like tuberculosis, carcinoma, any parasitic infection etc. Stool microscopy for parasite identification will be done at icddr,b parasitology lab as soon as possible after collection of stool samples. If nothing conclusive can be found, the participants may be requested to undergo preparations for upper GI endoscopy with biopsy, as they may benefit from further evaluation to identify the potential cause(s) of intervention failure and to determine an appropriate therapeutic course. It will also benefit others by validating the non-invasive bio-marker signature of Environmental Enteric Dysfunction. Participants who will undergo endoscopy will receive necessary treatments according to diagnosis.
Participants having celiac disease and clotting disorder (tested by prothrombin time / International Normalized Ratio coagulopathy) will be excluded from the study. Endoscopy of upper gastrointestinal tract will be done as per standards recommended by North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN0, American College of Gastroenterology (ACG) and American Society for Gastrointestinal Endoscopy (ASGE).
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Malnourished participants | Experimental | Dietary Supplement: Egg, Dietary Supplement: Milk, Drug: Albendazole/Pyrantel Pamoate, Behavioral: Nutritional counselling, Dietary Supplement: Micronutrient sprinklesAfter screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months. |
Who may qualify
- Ages
- 12 months to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (20 listed)
- Inclusion criteria for stunted children: All of the following criteria must be met for a subject to be eligible to participate in the study-
- Parent(s) willing to sign consent form
- Child age 12-18 months
- LAZ < -2
- Parent(s) willing to bring child to the study site every day for 3 months for nutritional therapy
Key exclusion criteria (12 listed)
- Exclusion criteria for stunted children: Meeting any of the following criteria will exclude a subject from study participation -
- Severe acute malnutrition (SAM), severe anemia (<8 g/dl), tuberculosis, other chronic diseases or any congenital disorder or deformity
- Diarrhoea: Ongoing episode of diarrhoea, history of persistent diarrhoea in the past month or history of acute diarrhoea in the past 7 days
- Known allergy to eggs or milk or milk intolerance
- Exclusion criteria for children who are at risk of stunting: Meeting any of the following criteria will exclude a subject from study participation -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EggAfter enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively. | Dietary supplement | Malnourished participants |
| MilkAfter enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively. | Dietary supplement | Malnourished participants |
| Albendazole/Pyrantel PamoateAs per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months. | Drug | Malnourished participants |
| Nutritional counsellingParents/caregivers will be given nutritional counselling | Behavioural | Malnourished participants |
| Micronutrient sprinklesFor the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months | Dietary supplement | Malnourished participants |
Primary outcome
Change in Length for Age Z score
Time frame: baseline and 3 months
For stunted child participants, length and age data will be collected before and after the intervention period (3 months) and changes in length for age Z score will be measured.For at risk of stunting child participants, length and age data will be collected before and after the intervention period (2 months) and changes in length for age Z score will be measured.
Change in Body Mass Index
Time frame: baseline and 2 months
For malnourished adult participants, height and and weight data will be collected before and after the intervention period (2 months) and changes in Body Mass Index will be measured.
19 secondary outcomes
Change in stool Regeneration gene 1 Beta (Reg 1B) biomarker level
Time frame: baseline and 3 months
Change in stool neopterin level
Time frame: baseline and 3 months
Change in stool myeloperoxidase level
Time frame: baseline and 3 months
Change in stool Alpha-1-antitrypsin level
Time frame: baseline and 3 months
Change in stool Calprotectin level
Time frame: baseline and 3 months
Change in stool TaqMan Array Card (TAC) result
Time frame: baseline and 3 months
Change in gut microbiota maturity status
Time frame: baseline and 3 months
Change in lactulose and rhamnose permeability test
Time frame: baseline and 3 months
Change in blood C-reactive protein level
Time frame: baseline and 3 months
Change in blood Alpha-1-acid glycoprotein level
Time frame: baseline and 3 months
Change in blood sCD14 level
Time frame: baseline and 3 months
Change in blood kynurenine Tryptophan ratio
Time frame: baseline and 3 months
Change in blood Glucagon-like peptide-2 level
Time frame: baseline and 3 months
Change in blood ferritin level
Time frame: baseline and 3 months
Change in blood zinc level
Time frame: baseline and 3 months
Change in blood pepsinogen I & II level
Time frame: baseline and 3 months
Change in blood Low density lipoprotein related receptor 1 (LRP1) level
Time frame: baseline and 3 months
Change in blood metabolomic profile
Time frame: baseline and 3 months
Change in small intestinal bacterial overgrowth (SIBO) status
Time frame: baseline and 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Feb 2022.
- Derived from this study: PubMed 38830904Pierce R, Jan NJ, Kumar P, Middleton J, Petri WA, Marie C. Persistent dysbiosis of duodenal microbiota in patients with controlled pediatric Crohn's disease after resolution of inflammation. Sci Rep. 2024 Jun 3;14(1):12668. doi: 10.1038/s41598-024-63299-y.
- Derived from this study: PubMed 36656867Hossain MS, Begum SMKN, Rahman MM, Parvez M, Mazumder RN, Sarker SA, Hasan MM, Fahim SM, Gazi MA, Das S, Mahfuz M, Ahmed T. Environmental enteric dysfunction and small intestinal histomorphology of stunted children in Bangladesh. PLoS Negl Trop Dis. 2023 Jan 19;17(1):e0010472. doi: 10.1371/journal.pntd.0010472. eCollection 2023 Jan.
- Derived from this study: PubMed 32706533Chen RY, Kung VL, Das S, Hossain MS, Hibberd MC, Guruge J, Mahfuz M, Begum SMKN, Rahman MM, Fahim SM, Gazi MA, Haque R, Sarker SA, Mazumder RN, Di Luccia B, Ahsan K, Kennedy E, Santiago-Borges J, Rodionov DA, Leyn SA, Osterman AL, Barratt MJ, Ahmed T, Gordon JI. Duodenal Microbiota in Stunted Undernourished Children with Enteropathy. N Engl J Med. 2020 Jul 23;383(4):321-333. doi: 10.1056/NEJMoa1916004.
- Derived from this study: PubMed 31665385Mahfuz M, Alam MA, Das S, Fahim SM, Hossain MS, Petri WA Jr, Ashorn P, Ashorn U, Ahmed T. Daily Supplementation With Egg, Cow Milk, and Multiple Micronutrients Increases Linear Growth of Young Children with Short Stature. J Nutr. 2020 Feb 1;150(2):394-403. doi: 10.1093/jn/nxz253.
- Derived from this study: PubMed 31646200Hossain MS, Das S, Gazi MA, Alam MA, Haque NMS, Mahfuz M, Ahmed T, Damman CJ. Association of faecal pH with childhood stunting: Results from a cross-sectional study. BMJ Paediatr Open. 2019 Sep 13;3(1):e000549. doi: 10.1136/bmjpo-2019-000549. eCollection 2019.
- Derived from this study: PubMed 28801442Mahfuz M, Das S, Mazumder RN, Masudur Rahman M, Haque R, Bhuiyan MMR, Akhter H, Sarker MSA, Mondal D, Muaz SSA, Karim ASMB, Borowitz SM, Moskaluk CA, Barratt MJ, Petri WA, Gordon JI, Ahmed T. Bangladesh Environmental Enteric Dysfunction (BEED) study: protocol for a community-based intervention study to validate non-invasive biomarkers of environmental enteric dysfunction. BMJ Open. 2017 Aug 11;7(8):e017768. doi: 10.1136/bmjopen-2017-017768.
- Individual participant dataSharing planned: No
Related trials for Malnutrition
Not yet recruitingObservational study
Prognostic Value of Functional-Nutritional Status in Older Adults With Acute Coronary Syndrome
Acute Coronary Syndromes (ACS)
RecruitingObservational study
Clinical and Laboratory Study of Methylmalonic Acidemia
Organic Acidemia, Methylmalonic Acidemia
Not yet recruiting
SHIFT-TB: Nutrition Intervention and Evaluation
Underweight, Overweight and Obesity
Not yet recruiting
Efficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults
Sleep Quality, Magnesium Deficiency
RecruitingObservational study
A Natural History Study of Bone and Mineral Disorders
Tumor Induced Osteomalcia, Osteomalacia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tahmeed Ahmed, PhD contact
Mustafa Mahfuz, MPH contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Egg, Milk and Albendazole/Pyrantel Pamoate in people with Malnutrition and Infection, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Tahmeed Ahmed, PhD (tahmeed@icddrb.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Length for Age Z score (time frame: baseline and 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02812615, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2022.